Mostrar el registro sencillo del ítem

dc.contributor.author
Roberti, Maria Paula  
dc.contributor.author
Arriaga, Juan Martín  
dc.contributor.author
Bianchini, Michele  
dc.contributor.author
Quintá, Héctor Ramiro  
dc.contributor.author
Bravo, Alicia Ines  
dc.contributor.author
Levy, Estrella Mariel  
dc.contributor.author
Mordoh, Jose  
dc.contributor.author
Barrio, Maria Marcela  
dc.date.available
2025-02-14T12:53:34Z  
dc.date.issued
2012-09  
dc.identifier.citation
Roberti, Maria Paula; Arriaga, Juan Martín; Bianchini, Michele; Quintá, Héctor Ramiro; Bravo, Alicia Ines; et al.; Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice; Landes Bioscience; Cancer Biology & Therapy; 13; 11; 9-2012; 1123-1140  
dc.identifier.issn
1538-4047  
dc.identifier.uri
http://hdl.handle.net/11336/254437  
dc.description.abstract
Triple negative breast cancers (TNBC) lacking hormone receptors and R-2 amplification are very aggressive tumors. Since relevant differences between primary tumors and metastases could arise during tumor progression as evidenced by phenotypic discordances reported for hormonal receptors or R-2 expression, in this analysis we studied changes that occurred in our TNBC model IIB-BR-G throughout the development of IIB-BR-G-MTS6 metastasis to the lymph nodes (LN) in nude mice, using an antibody-based protein array to characterize their expression profile. We also analyzed their growth kinetics, migration, invasiveness and cytoskeleton structure in vitro and in vivo. In vitro IIB-BR-G-MTS6 cells grew slower but showed higher anchorage independent growth. In vivo IIB-BR-G-MTS6 tumors grew significantly faster and showed a 100% incidence of LN metastasis after s.c. inoculation, although no metastasis was observed for IIB-BR-G. CCL3, IL1β, CXCL1, CSF2, CSF3, IGFB1, IL1α, IL6, IL8, CCL20, LUR, lGF and VGF were strongly upregulated in IIB-BR-G-MTS6 while CCL4, ICM3, CXCL12, TNFRSF18, FIGF were the most downregulated proteins in the metastatic cell line. IIB-BR-G-MTS6 protein expression profile could reflect a higher NFκB activation in these cells. In vitro, IIB-BR-G displayed higher migration but IIB-BR-G-MTS6 had more elevated matrigel invasion ability. In agreement with that observation, IIB-BR-G-MTS6 had an upregulated expression of MM1, MM9, MM13, LUR and GF. IIB-BR-G-MTS6 tumors presented also higher local lymphatic invasion than IIB-BR-G but similar lymphatic vessel densities. VGFC and VGF/B expression were higher both in vitro and in vivo for IIB-BR-G-MTS6. IIB-BR-G-MTS6 expressed more vimentin than IB-BR-G cells, which was mainly localized in the cellular extremities and both cell lines are -cadherin negative. Our results suggest that IIB-BR-G-MTS6 cells have acquired a pronounced epithelial-to-mesenchymal transition phenotype. rotein expression changes observed between primary tumor-derived IIB-BR-G and metastatic IIB-BR-G-MTS6 TNBC cells suggest potential targets involved in the control of metastasis.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Landes Bioscience  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Breast Cancer  
dc.subject
Proteomics  
dc.subject
Triple negative cancer  
dc.subject.classification
Biología Celular, Microbiología  
dc.subject.classification
Ciencias Biológicas  
dc.subject.classification
CIENCIAS NATURALES Y EXACTAS  
dc.title
Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2024-05-31T10:57:26Z  
dc.journal.volume
13  
dc.journal.number
11  
dc.journal.pagination
1123-1140  
dc.journal.pais
Estados Unidos  
dc.journal.ciudad
Austin  
dc.description.fil
Fil: Roberti, Maria Paula. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación Cáncer. Centro de Investigaciones Oncológicas; Argentina  
dc.description.fil
Fil: Arriaga, Juan Martín. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación Cáncer. Centro de Investigaciones Oncológicas; Argentina  
dc.description.fil
Fil: Bianchini, Michele. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación Cáncer. Centro de Investigaciones Oncológicas; Argentina  
dc.description.fil
Fil: Quintá, Héctor Ramiro. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina  
dc.description.fil
Fil: Bravo, Alicia Ines. Gobierno de la Provincia de Buenos Aires. Hospital Interzonal de Agudos Evita; Argentina  
dc.description.fil
Fil: Levy, Estrella Mariel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación Cáncer. Centro de Investigaciones Oncológicas; Argentina  
dc.description.fil
Fil: Mordoh, Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina. Fundación Cáncer. Centro de Investigaciones Oncológicas; Argentina  
dc.description.fil
Fil: Barrio, Maria Marcela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación Cáncer. Centro de Investigaciones Oncológicas; Argentina  
dc.journal.title
Cancer Biology & Therapy  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/abs/10.4161/cbt.21187  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.4161/cbt.21187